Download PDF
Thromb Haemost 1982; 47(01): 027-031
DOI: 10.1055/s-0038-1657118
Original Article
Schattauer GmbH Stuttgart

Clinical and Biological Activity of the Antiplatelet Agent Suloctidil in Treatment of Idiopathic Recurrent Vein Thrombosis (I.R.V.T.)

M Moriau
The Hematology Division, Hemostasis and Thrombosis Research Unit, Cliniques Universitaires Saint-Luc, University of Louvain (UCL), Brussels, Belgium
,
C Col-De Beys
The Hematology Division, Hemostasis and Thrombosis Research Unit, Cliniques Universitaires Saint-Luc, University of Louvain (UCL), Brussels, Belgium
,
E Pardonge
The Hematology Division, Hemostasis and Thrombosis Research Unit, Cliniques Universitaires Saint-Luc, University of Louvain (UCL), Brussels, Belgium
,
A Ferrant
The Hematology Division, Hemostasis and Thrombosis Research Unit, Cliniques Universitaires Saint-Luc, University of Louvain (UCL), Brussels, Belgium
› Author Affiliations
Further Information

Publication History

Received 08 April 1981

Accepted 14 December 1981

Publication Date:
13 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

A double blind cross over study with suloctidil (Sulocton, Continental Pharma) and placebo was carried out for 6 months in 31. patients with idiopathic recurrent vein thrombosis. They were previously unsuccessfully treated with vitamin K antagonists (VKA) (18 patients) or acetylsalicylic acid (ASA) (13 patients) combined or not with a fibrinolysis activator (theophylline nicotinate).

Clinical features, ultrasonic venous flow and biological parameters were controlled monthly during the 6 month treatment. Relevant improvement of clinical, ultrasonic and biological parameters was only observed under suloctidil therapy: during placebo administration 12 patients developed new thrombotic events complicated in 2 by pulmonary embolism while none occurred under suloctidil therapy.

Key words

Idiopathic recurrent vein thrombosis - Suloctidil - Platelet retention and aggregation - Platelet release - PF4 - Betathrom-boglobulin - Ultrasonic venous flow - Fibrinolysis activators
 

  • References

  • 1 Steele PP, Weily HS, Genton E. Platelet survival and adhesiveness in recurrent venous thrombosis. N Engl J Med 1973; 288: 1148-1152
    CrossrefPubMedGoogle Scholar
  • 2 Gallus AS, Hirsh J, Hull R, Van Aken WG. Diagnosis of venous thromboembolism. Semin Thromb Hemostas 1976; 2: 203-231
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Wu KK, Barnes RW, Hoak JC. Platelet hyperaggregability in idiopathic recurrent deep vein thrombosis. Circulation 1976; 53: 687-691
    CrossrefPubMedGoogle Scholar
  • 4 Steele P, Ellis Jr J, Genton E. Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. Am J Med 1978; 64: 441-445
    CrossrefPubMedGoogle Scholar
  • 5 Clagett GP, Collins GJ. Platelets, thromboembolism and the clinical utility of antiplatelet drugs. Surg Gynecol Obstet 1978; 147: 257-279
    PubMedGoogle Scholar
  • 6 Steele P. Trial of Dipyridamole-Aspirin in recurring venous thrombosis. Lancet 1980; 2: 1328-1329
    PubMedGoogle Scholar
  • 7 Hume M, Sevitt S, Thomas DP. Venous thrombosis and pulmonary embolism. Harvard University Press Cambridge; Massachusets: 1970
    Google Scholar
  • 8 Gallus AS, Walker IR, Hirsh J, Halasah G, Evans G. Platelet survival, fibrinolytic activity, antithrombin III level and fibrinogen survival in venous thromboembolism. Abst 209 Proc Vth Cong Int Soc Thromb Haemostas Paris 1975
    PubMedGoogle Scholar
  • 9 Davies GC, Salzman EW. The treatment of venous thrombosis and pulmonary embolism. In: Venous and arterial thrombos. Ed. by Joist JH, Sherman LA. Grane and Stratton Inc.; 133-157 New York: 1978
    Google Scholar
  • 10 Penner JA. Hypercoagulation and thrombosis. Med Clin N Am 1980; 64: 743-759
    CrossrefPubMedGoogle Scholar
  • 11 Hirsh J, Mc Bride JA. Increased platelet adhesiveness in recurrent venous thrombosis and pulmonary embolism. Br Med J 1965; 2: 797-799
    CrossrefPubMedGoogle Scholar
  • 12 Walsh PN. The possible role of platelet coagulant activities in the pathogenesis of venous thrombosis. Thrombos Diathes Haemorrh 1975; 33: 435-443
    PubMedGoogle Scholar
  • 13 Abrahamsen AF. Platelet survival studies in man. Scand J Haematol 1968; (03) 7-53
    PubMedGoogle Scholar
  • 14 Harker LA, Slichter SJ. Platelet and fibrinogen consumption in man. N Engl J Med 1972; 287: 999-1005
    CrossrefPubMedGoogle Scholar
  • 15 Smith JB, Ingerman C, Kocsis JJ. Formation of prostaglandins during the aggregation of human blood platelets. J Clin Invest 1973; 52: 965-969
    CrossrefPubMedGoogle Scholar
  • 16 Ganström E, Kindahl H, Samuelsson B. Radio-immunoassay f. TXB2 . Ann Lett 1976; 9: 611-627
    PubMedGoogle Scholar
  • 17 Pepper D. Measurement of platelet release reaction. In Thromboembolism. A new approach to therapy. Eds. Mitchel JRA, Domenet JG. 55-68 Acad Press; London: 1977
    Google Scholar
  • 18 Smith RC, Duncanson J, Ruckley CV, Webber RV, Allan NC, Dawer J, Bolton AE, Hunter WM, Pepper DS, Cash JD. Betathromboglobulin and deep vein thrombosis. Thromb Haemostas 1978; 39: 338-346
    PubMedGoogle Scholar
  • 19 Hirsh J. Blood tests for the diagnosis of venous and arterial thrombosis. Blood 1981; 57: 1-8
    PubMedGoogle Scholar
  • 20 Hirsh J, Gallus AS. Hypercoagulability. In: Recent Advances in Haematology 2. Eds. Hoffbrand AV, Brain MC, Hirsh J. Churchill Livingstone, Edinburgh; London, New York: 1977: 431-451
    Google Scholar
  • 21 Isacson S, Nilsson IM. Defective fibrinolysis in blood and vein walls in recurrent idiopathic venous thrombosis. Acta Chir Scand 1972; 138: 313-319
    PubMedGoogle Scholar
  • 22 Nilsson IM. Phenformin and ethylestrenol in recurrent venous thrombosis. In Progress in Chemical Fibrinolysis and Thrombolysis. vol. 1 Eds. Davidson JF, Samama MM, Desnoyers PC. 1-12 Raven Press; New York: 1975
    Google Scholar
  • 23 Browse NL, Gray L, Jarret PE, Morland M. Blood and vein wall fibrinolytic activity in health and vascular disease. Br Med J 1977; 1: 478-481
    CrossrefPubMedGoogle Scholar
  • 24 Ciavarella N, Schiavoni M, Parato M, Oreste A, Pilolli D, Ciccolella A, Coviello M. Defective fibrinolytic activity but normal prostacycline like activity in vein walls of patients with recurrent venous thrombosis. In: Progress in chemical fibrinolysis and thrombolysis. vol IV. Eds. Davidson JF. 115-123 Churchill Livingstone, Edinburgh; London, New York: 1979
    Google Scholar
  • 25 Turpie AGG, Hirsh J. Platelet suppressant therapy. In venous and arterial thrombosis. Eds. Joist JH, Sherman LA. 339-358 Grane and Stratton Inc.; New York: 1978
    Google Scholar
  • 26 Isacson S, Nilsson IM. Effect of treatment with combined phenformin and ethylestrenol on the coagulation and fibrinolytic systems. Scand J Haematol 1970; 7: 404-408
    PubMedGoogle Scholar
  • 27 Jarret PEM, Morland M, Browse NL. Idiopathic recurrent superficial thrombophlebitis. Treatment with fibrinolytic enbrancement. Br Med J 1977; 1: 933-937
    CrossrefPubMedGoogle Scholar
  • 28 Bielawiec M, Mysliwiec M, Perzanowski A. Combined therapy with Phenformin plus Stanozolol in patients with occlusive arterial disease and recurrent venous thrombosis. In: Progress in Chemical fibrinolysis and thrombolysis. vol. 3 Eds. Davidson JF, Rowan RM, Samama MM, Denoy PC. 507-512 Raven Press; New York: 1978
    Google Scholar
  • 29 de Gaetano G, Miragliotta G, Roncucci R, Lansen J, Lambelin G. Suloctidil: A novel inhibitor of platelet aggregation in human beings. Thromb Res 1976; 8: 361-371
    CrossrefPubMedGoogle Scholar
  • 30 Roba J, Bourgain R, Andries R, Claeys M, Van Opstal W, Lambelin G. Antagonism by suloctidil of arterial thrombus formation in rats. Thromb Res 1976; 9: 585-594
    CrossrefPubMedGoogle Scholar
  • 31 Mills DCB, Macfarlane DE. Depletion of platelet amine storage granules by the antithrombotic agent, suloctidil. Thromb Haemostas 1977; 38: 1010-1017
    PubMedGoogle Scholar
  • 32 Gurewich V, Lipinski B. Evaluation of antithrombotic properties of suloctidil in comparision with aspirin and dipyridamole. Thromb Res 1976; 9: 101-108
    CrossrefPubMedGoogle Scholar
  • 33 Moriau M, Ferrant A. Antivitamines K et antiagrégants plaquettaires dans la prévention des thromboses. Acta Clin Belg 1977; 32: 409-421
    CrossrefPubMedGoogle Scholar
  • 34 Roba J, Claeys M, Roet R, Van Opstal W, Lambelin G. Erythrocyte membranes as a target for antithrombotic agents. Proc Xlth Int Cong Angiology, Prague. 1978: 96-98
    PubMedGoogle Scholar
  • 35 Roncucci R, De Hertogh R, Dormandy JA, Doumont J, Gurewich V, Lambelin G, Lansen J, Rottiers R, Souridis E, Van Stalle F, Versee L. Effects of long-term treatment with suloctidil on blood viscosity, erythrocyte deformability and total fibrinogen plasma levels in diabetic patients. Arzneim Forsch 1979; 29: 682-684
    PubMedGoogle Scholar
  • 36 Villa S, Cavenaghi AE, de Gaetano G. Suloctidil does not inhibit vascular prostacyclin activity in rats. Thromb Haemostas 1979; 42: 368
    PubMedGoogle Scholar
  • 37 Bowie EJW, Owen OHA, Thompson JH, Didisheim P. A test of platelet adhesiveness. Mayo Clin Proc 1969; 44: 306-308
    PubMedGoogle Scholar
  • 38 Born GVR, Cross MJ. The aggregation of blood platelets. J. Physiol 1963; 168: 178-195
    CrossrefPubMedGoogle Scholar
  • 39 Hurlet BirkJensen A, Legrand MonsieurA, Masure R. Analysis of heparin neutralizing assay conditions. Thromb Res 1978; 13: 609-614
    CrossrefPubMedGoogle Scholar
  • 40 Bolton AE, Ludlan CA, Moore S, Pepper DS, Cash JD. Three approaches to the radio-immunoassay of human beta-thromboglobulin. Br J Haematol 1976; 33: 233-238
    CrossrefPubMedGoogle Scholar
  • 41 Gram HC. A new method for determination of the fibrin percent in blood and plasma. J Biol Chem 1921; 49: 279-293
    PubMedGoogle Scholar
  • 42 Vermylen C, Verstraete M. A simple method for the assay of factor VIII using 25 microliters of capillary blood. Br J Haematol 1968; 14: 241-245
    CrossrefPubMedGoogle Scholar
  • 43 Laurell CB. Antigen antibody crossed electrophoresis. Ann Biochem 1965; 10: 358-361
    CrossrefPubMedGoogle Scholar
  • 44 Macfarlane DE, Stibbe J, Kirby EP, Zucker HB, Grant RA, McPherson J. A method for assaying von Willebrand factor (Ristocetine cofactor). Thrombos Diathes Haemorrh 1975; 34: 306-310
    PubMedGoogle Scholar
  • 45 Von Kaulla KN, Schulz RL. Method for the evaluation of human fibrinolysis. Studies with 2 combined technics. Am J Clin Pathol 1958; 29: 104-109
    CrossrefPubMedGoogle Scholar
  • 46 Buckell M. The effect of citrate on euglobulin methods of estimating fibrinolytic activity. J Clin Pathol 1958; 2: 403-410
    PubMedGoogle Scholar
  • 47 Doyle DJ, Chesterman CN, Cade JF, McGready JR, Rennie GC, Morgan FJ. Plasma concentrations of platelet specific proteins correlated with platelet survival. Blood 1980; 55: 82-84
    PubMedGoogle Scholar
  • 48 Moriau M, Ferrant A, Col-De Beys C, Hurlet A, Chalant C, Ponlot R, Jaumin P, Goenen M, Masure R, Lansen J, Roncucci R, Van Stalle F, Lambelin G. Suloctidil and platelet functions in man. 112 Abst Intern Confer on atherosclerosis. Milan 1977;
    PubMedGoogle Scholar
  • 49 Moriau M, Roncucci R, Van Stalle F, Lambelin G. Effect of suloctidil in various forms of thromboembolic complications. 247 Abstract of Fifth International Congress on Thromboembolism. Bologne 1978;
    PubMedGoogle Scholar